SHIFT SLS ValueSets Implementation Guide
0.1.0 - ci-build

SHIFT SLS ValueSets Implementation Guide, published by SHIFT-Task-Force. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/SHIFT-Task-Force/SLS-ValueSets/ and changes regularly. See the Directory of published versions

## ValueSet: clinical codes that indicate HIV

Official URL: http://SHIFT-Task-Force.github.io/slsValueSets/ValueSet/SamhsaSensitiveHIV | Version: 0.1.0
Active as of 2016-09-09 | Computable Name: SamhsaSensitiveHIV
Usage:Clinical Focus: HIV/AIDS information sensitivity

HIV/AIDS information

- SAMHSA C2S HIV/AIDS Information
  - ValueSet 2.16.840.1.113762.1.4.1142.23 // HCPCS
  - ValueSet 2.16.840.1.113762.1.4.1142.24 // ICD9CM
  - ValueSet 2.16.840.1.113762.1.4.1142.25 // LOINC
  - ValueSet 2.16.840.1.113762.1.4.1142.26 // RXNORM
  - ValueSet 2.16.840.1.113762.1.4.1142.27 // SNOMED-CT
  - ValueSet 2.16.840.1.113762.1.4.1142.60 // CPT
- SAMHSA Test C2S HIV/AIDS Information Sensitivity
  - ValueSet 2.16.840.1.113762.1.4.1142.67 // SNOMEDCD

References

This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)

### Logical Definition (CLD)

This value set includes codes based on the following rules:

- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS information Sensitivity
- Import all the codes that are contained in Test C2S HIV/AIDS Information Sensitivity

### Expansion

Expansion from tx.fhir.org based on:

- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS information Sensitivity v20160909 (ValueSet)
- valueset Test C2S HIV/AIDS Information Sensitivity v20190216 (ValueSet)

This value set contains 162 concepts

System | Version | Code | Display (en) | JSON | XML
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 0575F | Hiv rna control plan of care, documented (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3292F | Hiv testing ordered or documented and reviewed during the first or second prenatal visit (pre-cr) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3490F | History of aids-defining condition (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3491F | Hiv indeterminate (infants of undetermined hiv status born of hiv-infected mothers) (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3492F | History of nadir cd4+ cell count <350 cells/mm (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3493F | No history of nadir cd4+ cell count <350 cells/mmand no history of aids-defining condition (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3494F | Cd4+ cell count <200 cells/mm3 (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3495F | Cd4+ cell count 200 - 499 cells/mm3 (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3496F | Cd4+ cell count >=500 cells/mm3 (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3497F | Cd4+ cell percentage <15% (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3498F | Cd4+ cell percentage >/=15% (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3500F | Cd4+ cell count or cd4+ cell percentage documented as performed (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3502F | Hiv rna viral load below limits of quantification (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3503F | Hiv rna viral load not below limits of quantification (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3510F | Documentation that tuberculosis (tb) screening test performed and results interpreted (hiv) (ibd) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3511F | Chlamydia and gonorrhea screenings documented as performed (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3512F | Syphilis screening documented as performed (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3513F | Hepatitis b screening documented as performed (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3514F | Hepatitis c screening documented as performed (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 3515F | Patient has documented immunity to hepatitis c (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 4149F | Hepatitis b vaccine injection administered or previously received (hep-c, hiv) (ibd) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 4270F | Patient receiving potent antiretroviral therapy for 6 months or longer (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 4271F | Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 4274F | Influenza immunization administered or previously received (hiv) (p-esrd) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 4276F | Potent antiretroviral therapy prescribed (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 4279F | Pneumocystis jiroveci pneumonia prophylaxis prescribed (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 4280F | Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low cd4+ cell count or percentage (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 4290F | Patient screened for injection drug use (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 4293F | Patient screened for high-risk sexual behavior (hiv) |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 86689 | Confirmation test for antibody to Human T-cell lymphotropic virus (HTLV) or HIV |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 86701 | Analysis for antibody to HIV -1 virus |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 86702 | Analysis for antibody to HIV-2 virus |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 86703 | Analysis for antibody to HIV-1 and HIV-2 virus |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87389 | Detection test by immunoassay technique for HIV-1 antigen and HIV-1 and HIV-2 antibodies |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87390 | Detection test by immunoassay technique for HIV-1 antigen |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87391 | Detection test by immunoassay technique for HIV-2 antigen |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87534 | Detection test by nucleic acid for HIV-1 virus, direct probe technique |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87535 | Detection test by nucleic acid for HIV-1 virus, amplified probe technique |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87536 | Detection test by nucleic acid for HIV-1 virus, quantification |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87537 | Detection test by nucleic acid for HIV-2 virus, direct probe technique |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87538 | Detection test by nucleic acid for HIV-2 virus, amplified probe technique |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87539 | Detection test by nucleic acid for HIV-2 virus, quantification |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87900 | Infectious agent drug susceptibility analysis |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87901 | Analysis test by nucleic acid for HIV-1 virus |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87903 | Analysis test by nucleic acid for HIV-1 virus, first through 10 drugs tested |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87904 | Analysis test by nucleic acid for HIV-1 virus, each additional drug tested |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | 87906 | Analysis test by nucleic acid for HIV-1 virus, other region |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening |  |
`http://www.nlm.nih.gov/research/umls/hcpcs` | 2024 | S3645 | Hiv-1 antibody testing of oral mucosal transudate |  |
`http://hl7.org/fhir/sid/icd-9-cm` | 2013 | 136.3 | Pneumocystosis |  |
`http://hl7.org/fhir/sid/icd-9-cm` | 2013 | 176.9 | Kaposi's sarcoma, unspecified site |  |
`http://hl7.org/fhir/sid/icd-9-cm` | 2013 | 42 | Operations on esophagus |  |
`http://loinc.org` | 2.77 | 10901-7 | HIV 2 gp125 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 10902-5 | HIV 2 gp36 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 11078-3 | HIV 2 gp80 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 11079-1 | HIV 2 p26 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 11080-9 | HIV 2 p53 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 11081-7 | HIV 2 p56 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 11082-5 | HIV 2 p68 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 13920-4 | HIV 2 p41 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 21334-8 | HIV 2 gp105 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 21335-5 | HIV 2 gp120 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 21336-3 | HIV 2 gp15 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 21337-1 | HIV 2 gp34 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 21338-9 | HIV 2 p31 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 21339-7 | HIV 2 p55 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 21340-5 | HIV 2 p58 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 22358-6 | HIV 2 Ab [Units/volume] in Serum |  |
`http://loinc.org` | 2.77 | 25841-8 | HIV 2 proviral DNA [Presence] in Blood by NAA with probe detection |  |
`http://loinc.org` | 2.77 | 25842-6 | HIV 2 proviral DNA [Presence] in Specimen by NAA with probe detection |  |
`http://loinc.org` | 2.77 | 30361-0 | HIV 2 Ab [Presence] in Serum or Plasma by Immunoassay |  |
`http://loinc.org` | 2.77 | 31073-0 | HIV 2 Ab band pattern [Interpretation] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 33806-1 | HIV 2 IgG Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 33807-9 | HIV 2 IgG Ab [Presence] in Serum |  |
`http://loinc.org` | 2.77 | 34699-9 | HIV 2 proviral DNA [Presence] in Serum or Plasma by NAA with probe detection |  |
`http://loinc.org` | 2.77 | 42768-2 | HIV 1 and 2 Ab [Interpretation] in Serum Narrative |  |
`http://loinc.org` | 2.77 | 43185-8 | HIV 1 and 2 Ab band pattern [Interpretation] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 45212-8 | HIV 2 p31+p34 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 47029-4 | HIV 2 Ab [Presence] in Cerebral spinal fluid by Immunoblot |  |
`http://loinc.org` | 2.77 | 51786-2 | HIV 2 Ab Signal/Cutoff in Serum or Plasma by Immunoassay |  |
`http://loinc.org` | 2.77 | 5224-1 | HIV 2 Ab [Units/volume] in Serum or Plasma by Immunoassay |  |
`http://loinc.org` | 2.77 | 5225-8 | HIV 2 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 56888-1 | HIV 1+2 Ab+HIV1 p24 Ag [Presence] in Serum or Plasma by Immunoassay |  |
`http://loinc.org` | 2.77 | 57976-3 | HIV 2 gp140 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 57977-1 | HIV 2 p16 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 57978-9 | HIV 2 p34 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 58900-2 | HIV 1+2 Ab+HIV1 p24 Ag [Units/volume] in Serum or Plasma by Immunoassay |  |
`http://loinc.org` | 2.77 | 62456-9 | HIV 2 p15 Ab [Presence] in Serum by Immunoblot |  |
`http://loinc.org` | 2.77 | 6429-5 | HIV identified in Blood by Organism specific culture |  |
`http://loinc.org` | 2.77 | 6430-3 | HIV identified in Semen by Organism specific culture |  |
`http://loinc.org` | 2.77 | 6431-1 | HIV identified in Specimen by Organism specific culture |  |
`http://loinc.org` | 2.77 | 69353-1 | HIV 2 RNA [Presence] in Serum or Plasma by NAA with probe detection |  |
`http://loinc.org` | 2.77 | 69354-9 | HIV 2 RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection |  |
`http://loinc.org` | 2.77 | 69668-2 | HIV 1 and 2 Ab [Identifier] in Serum or Plasma by Rapid immunoassay |  |
`http://loinc.org` | 2.77 | 7919-4 | HIV 2 Ab [Presence] in Serum |  |
`http://loinc.org` | 2.77 | 9836-8 | HIV proviral DNA [Presence] in Blood by Probe with amplification |  |
`http://loinc.org` | 2.77 | LP14307-0 | HIV 1 |  |
`http://loinc.org` | 2.77 | LP16715-2 | HIV 1+2 |  |
`http://loinc.org` | 2.77 | LP16716-0 | HIV 2 |  |
`http://loinc.org` | 2.77 | LP29063-2 | HIV reverse transcriptase gene |  |
`http://loinc.org` | 2.77 | LP30901-0 | HIV protease gene |  |
`http://loinc.org` | 2.77 | LP32723-6 | HIV reverse transcriptase+protease gene |  |
`http://loinc.org` | 2.77 | LP36650-7 | HIV 1 & 2 |  |
`http://loinc.org` | 2.77 | LP36876-8 | HIV nucleoside reverse transcriptase gene |  |
`http://loinc.org` | 2.77 | LP36877-6 | HIV nonnucleoside reverse transcriptase gene |  |
`http://loinc.org` | 2.77 | LP38420-3 | HIV identified |  |
`http://loinc.org` | 2.77 | LP38459-1 | HIV 1+2 Ab |  |
`http://loinc.org` | 2.77 | LP38463-3 | HIV 2 Ab |  |
`http://loinc.org` | 2.77 | LP62411-1 | HIV 1+O+2 Ab |  |
`http://www.nlm.nih.gov/research/umls/rxnorm` | 05062024 | 152535 | Zovirax |  |
`http://www.nlm.nih.gov/research/umls/rxnorm` | 05062024 | 281 | acyclovir |  |
`http://snomed.info/sct` | http://snomed.info/sct/731000124108/version/20240301 | 111880001 | Acute human immunodeficiency virus infection (disorder) |  |
`http://snomed.info/sct` | http://snomed.info/sct/731000124108/version/20240301 | 420721002 | Acquired immunodeficiency syndrome-associated disorder (disorder) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 0575F | HIV RNA control plan of care, documented (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3292F | HIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3490F | History of AIDS-defining condition (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3491F | HIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3492F | History of nadir CD4+ cell count <350 cells/mm3 (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3493F | No history of nadir CD4+ cell count <350 cells/mm3 and no history of AIDS-defining condition (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3494F | CD4+ cell count <200 cells/mm3 (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3495F | CD4+ cell count 200 - 499 cells/mm3 (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3496F | CD4+ cell count >=500 cells/mm3 (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3497F | CD4+ cell percentage <15% (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3498F | CD4+ cell percentage >=15% (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3500F | CD4+ cell count or CD4+ cell percentage documented as performed (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3502F | HIV RNA viral load below limits of quantification (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3503F | HIV RNA viral load not below limits of quantification (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3510F | Documentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3511F | Chlamydia and gonorrhea screenings documented as performed (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3512F | Syphilis screening documented as performed (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3513F | Hepatitis B screening documented as performed (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3514F | Hepatitis C screening documented as performed (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 3515F | Patient has documented immunity to Hepatitis C (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 4149F | Hepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 4270F | Patient receiving potent antiretroviral therapy for 6 months or longer (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 4271F | Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 4274F | Influenza immunization administered or previously received (HIV) (P-ESRD) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 4276F | Potent antiretroviral therapy prescribed (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 4279F | Pneumocystis jiroveci pneumonia prophylaxis prescribed (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 4280F | Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 4290F | Patient screened for injection drug use (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 4293F | Patient screened for high-risk sexual behavior (HIV) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 86689 | Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 86701 | Antibody; HIV-1 |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 86702 | Antibody; HIV-2 |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 86703 | Antibody; HIV-1 and HIV-2, single result |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87389 | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87390 | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87391 | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-2 |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87534 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87535 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87536 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87537 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87538 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87539 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87900 | Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87901 | Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87903 | Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87904 | Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure) |  |
`http://www.ama-assn.org/go/cpt` | 2024 | 87906 | Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion) |  |

Explanation of the columns that may appear on this page:

Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System | The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code | The code (used as the code in the resource instance)
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition | An explanation of the meaning of the concept
Comments | Additional notes about how to use the code

History

Date | Action | Author | Verifier | Comment
2023-01-31 | revise | John Moehrke |  | Administrative touchup to add history
2022-07-27 | create | John Moehrke | John F. Moehrke | Initial ValueSet as per the C2S layout